[go: up one dir, main page]

PE20210321A1 - Anticuerpos biespecificos contra dll3-cd3 - Google Patents

Anticuerpos biespecificos contra dll3-cd3

Info

Publication number
PE20210321A1
PE20210321A1 PE2020001978A PE2020001978A PE20210321A1 PE 20210321 A1 PE20210321 A1 PE 20210321A1 PE 2020001978 A PE2020001978 A PE 2020001978A PE 2020001978 A PE2020001978 A PE 2020001978A PE 20210321 A1 PE20210321 A1 PE 20210321A1
Authority
PE
Peru
Prior art keywords
antibodies against
dll3
antigen
specifically binds
against dll3
Prior art date
Application number
PE2020001978A
Other languages
English (en)
Inventor
Susanne Hipp
Paul Adam
Michael Dziegelewski
Rajkumar Ganesan
Philip Nicholas Gorman
Priyanka Gupta
Pankaj Gupta
Justin Scheer
Vladimir H Voynov
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20210321A1 publication Critical patent/PE20210321A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a anticuerpos biespecificos que comprende una primera unidad de fijacion al antigeno que se fija especificamente a DLL3 y una segunda unidad de fijacion al antigeno que se fija especificamente a CD3, utiles en el tratamiento de enfermedades cancerosas, tambien se refiere a acidos nucleicos, un vector de expresion, una celula huesped, un metodo de produccion y una composicion farmaceutica
PE2020001978A 2018-06-09 2019-06-07 Anticuerpos biespecificos contra dll3-cd3 PE20210321A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18176888 2018-06-09
EP18176889 2018-06-09
EP19159321 2019-02-26
PCT/EP2019/064942 WO2019234220A1 (en) 2018-06-09 2019-06-07 Dll3-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
PE20210321A1 true PE20210321A1 (es) 2021-02-16

Family

ID=66752128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001978A PE20210321A1 (es) 2018-06-09 2019-06-07 Anticuerpos biespecificos contra dll3-cd3

Country Status (32)

Country Link
US (3) US11332541B2 (es)
EP (2) EP4566621A3 (es)
JP (2) JP7133043B2 (es)
KR (1) KR20210018311A (es)
CN (7) CN119529097A (es)
AU (1) AU2019280900A1 (es)
BR (1) BR112020022898A2 (es)
CA (1) CA3099956A1 (es)
CL (1) CL2020003105A1 (es)
CO (1) CO2020015172A2 (es)
CR (1) CR20200601A (es)
DK (1) DK3802598T3 (es)
EC (1) ECSP20084864A (es)
ES (1) ES3021463T3 (es)
FI (1) FI3802598T3 (es)
HR (1) HRP20250443T1 (es)
HU (1) HUE071620T2 (es)
IL (1) IL279235A (es)
JO (1) JOP20200313A1 (es)
LT (1) LT3802598T (es)
MA (1) MA52742B1 (es)
MX (1) MX2020013348A (es)
MY (1) MY199655A (es)
PE (1) PE20210321A1 (es)
PH (1) PH12020552080A1 (es)
PL (1) PL3802598T3 (es)
RS (1) RS66693B1 (es)
SA (1) SA520420748B1 (es)
SG (1) SG11202011134XA (es)
SI (1) SI3802598T1 (es)
TW (1) TWI848953B (es)
WO (1) WO2019234220A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
MX2020011914A (es) 2018-05-08 2021-01-29 Phanes Therapeutics Inc Anticuerpos anti-dll3 y usos de los mismos.
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
US12534516B2 (en) * 2018-10-22 2026-01-27 International Aids Vaccine Initiative Anti-HIV antibodies
TWI878355B (zh) * 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
JP2023512297A (ja) * 2020-01-31 2023-03-24 ゲンサン バイオファーマ インコーポレイテッド 二重特異性ｔ細胞エンゲージャー
PE20230077A1 (es) * 2020-03-31 2023-01-11 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2021236998A2 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
CN111551733A (zh) * 2020-05-29 2020-08-18 武汉大学 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
AU2021372988A1 (en) * 2020-11-06 2023-06-22 Board Of Regents, The University Of Texas System Methods and systems for classification and treatment of small cell lung cancer
CA3204628A1 (en) * 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
CN117425500A (zh) * 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
AU2022273136A1 (en) * 2021-05-08 2023-10-26 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
CA3217141A1 (en) * 2021-05-10 2022-11-17 Nooshin Hashemi SADRAEI Dosing regimen for combination therapy targeting dll3 and pd-1
CN118076878A (zh) 2021-09-02 2024-05-24 勃林格殷格翰国际公司 确定未来颜色值或相应属性及其装置的方法
JP2025500952A (ja) * 2021-12-23 2025-01-15 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｄｌｌ３抗体、その抗体－薬物複合体及びその医薬的使用
EP4477670A1 (en) * 2022-02-10 2024-12-18 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Bispecific antigen-binding molecule and use thereof
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
WO2023246885A1 (zh) * 2022-06-23 2023-12-28 江苏恒瑞医药股份有限公司 特异性结合dll3和cd3的抗原结合分子及其医药用途
US20240166629A1 (en) 2022-10-26 2024-05-23 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
AU2023370101A1 (en) 2022-10-26 2025-06-05 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024089006A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
IL320471A (en) * 2022-12-08 2025-06-01 Amgen Inc Methods for treating DLL3-expressing cancers
WO2024159174A1 (en) * 2023-01-27 2024-08-02 The United States Goverment As Represented By The Department Of Veterans Affairs Compositions for treating tauopathies and methods of use thereof
WO2024179470A1 (zh) 2023-02-27 2024-09-06 苏州盛迪亚生物医药有限公司 抗dll3抗体、其抗体-药物偶联物及其医药用途
AU2024276141A1 (en) 2023-05-19 2025-11-20 Boehringer Ingelheim International Gmbh Uses of t cell engaging proteins in the treatment of cancer
WO2025131024A1 (zh) * 2023-12-22 2025-06-26 江苏恒瑞医药股份有限公司 一种包含特异性结合dll3和cd3的双特异性抗体的药物组合物
WO2025146127A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 针对dll3和cd3的双特异性抗体及其应用
WO2025184731A1 (en) * 2024-03-04 2025-09-12 Zymeworks Bc Inc. Trispecific antibody constructs targeting dll3 and methods of use thereof
WO2025193578A1 (en) 2024-03-11 2025-09-18 Amgen Inc. Method of treating brain metastases in subjects with a dll3-positive cancer
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168A (en) 1837-04-17 Improvement in fire-arms
US5731A (en) 1848-08-22 Elisha k
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
WO2005004809A2 (en) 2003-07-01 2005-01-20 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CA2609319C (en) 2005-07-15 2014-02-04 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
KR20080087822A (ko) 2005-12-16 2008-10-01 제넨테크, 인크. 신경아교종을 진단하고, 예측하고, 치료하는 방법
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
RU2571929C2 (ru) 2009-09-01 2015-12-27 Дженентек, Инк. Улучшенная очистка белка посредством модифицированного элюирования белка а
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
HRP20180952T1 (hr) * 2010-01-29 2018-07-27 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
WO2011103465A2 (en) 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
SG10201605048XA (en) 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
TW201321405A (zh) 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
MX359384B (es) 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
DK2794905T3 (da) * 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
JP6089047B2 (ja) 2012-02-24 2017-03-01 アッヴィ・ステムセントルクス・エル・エル・シー Ｄｌｌ３モジュレーター及び使用方法
CN114163530B (zh) 2012-04-20 2025-04-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2014018572A2 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
US20150016666A1 (en) 2012-11-02 2015-01-15 Google Inc. Method and Apparatus for Determining Geolocation of Image Contents
JP6385357B2 (ja) 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN105307676A (zh) 2013-04-05 2016-02-03 豪夫迈·罗氏有限公司 抗il-4抗体和双特异性抗体及其用途
CN118561989A (zh) 2013-04-29 2024-08-30 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3192812B1 (en) * 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US20170275373A1 (en) * 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
MX388301B (es) 2014-09-03 2025-03-19 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
AR102522A1 (es) 2014-11-06 2017-03-08 Hoffmann La Roche Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
KR20180021875A (ko) * 2015-06-30 2018-03-05 베링거 인겔하임 인터내셔날 게엠베하 다중특이적 결합 단백질
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
CA2995709A1 (en) * 2015-08-17 2017-02-23 Macrogenics,Inc. Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
EP3458478B1 (en) 2016-05-18 2021-01-06 Boehringer Ingelheim International GmbH Anti pd-1 and anti-lag3 antibodies for cancer treatment
TWI817974B (zh) * 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
CA3096123A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
KR102839606B1 (ko) 2018-12-31 2025-07-29 삼성디스플레이 주식회사 색변환 기판 및 표시 장치
CN117377694A (zh) * 2021-03-24 2024-01-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途

Also Published As

Publication number Publication date
AU2019280900A1 (en) 2020-11-19
JOP20200313A1 (ar) 2020-12-06
JP2021526816A (ja) 2021-10-11
US11332541B2 (en) 2022-05-17
BR112020022898A2 (pt) 2021-02-23
CN119499365A (zh) 2025-02-25
PL3802598T3 (pl) 2025-06-09
CN112513092A (zh) 2021-03-16
US12173083B2 (en) 2024-12-24
JP7133043B2 (ja) 2022-09-07
CA3099956A1 (en) 2019-12-12
TWI848953B (zh) 2024-07-21
FI3802598T3 (fi) 2025-03-18
CN119490599A (zh) 2025-02-21
IL279235A (en) 2021-01-31
RS66693B1 (sr) 2025-05-30
TW202016151A (zh) 2020-05-01
US20220251236A1 (en) 2022-08-11
EP4566621A3 (en) 2025-08-20
US20190375849A1 (en) 2019-12-12
EP3802598A1 (en) 2021-04-14
MX2020013348A (es) 2021-03-09
HUE071620T2 (hu) 2025-09-28
MY199655A (en) 2023-11-14
SG11202011134XA (en) 2020-12-30
ECSP20084864A (es) 2021-05-31
CN119241717A (zh) 2025-01-03
CL2020003105A1 (es) 2021-06-11
CN120131936A (zh) 2025-06-13
HRP20250443T1 (hr) 2025-06-06
CN119285788A (zh) 2025-01-10
CN119529097A (zh) 2025-02-28
KR20210018311A (ko) 2021-02-17
JP2022180379A (ja) 2022-12-06
SI3802598T1 (sl) 2025-08-29
LT3802598T (lt) 2025-04-10
PH12020552080A1 (en) 2021-05-31
US12528879B2 (en) 2026-01-20
CR20200601A (es) 2021-01-26
DK3802598T3 (da) 2025-03-31
WO2019234220A1 (en) 2019-12-12
ES3021463T3 (en) 2025-05-27
CN112513092B (zh) 2024-11-08
SA520420748B1 (ar) 2023-12-06
MA52742B1 (fr) 2025-03-28
MA52742A (fr) 2021-04-14
US20230295337A1 (en) 2023-09-21
EP3802598B1 (en) 2025-02-12
EP4566621A2 (en) 2025-06-11
CO2020015172A2 (es) 2020-12-21

Similar Documents

Publication Publication Date Title
PE20210321A1 (es) Anticuerpos biespecificos contra dll3-cd3
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
CL2023002690A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645)
PE20201341A1 (es) Anticuerpos de union a gprc5d
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
PE20221262A1 (es) Anticuerpos terapeuticos y sus usos
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
PE20170263A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
PE20170264A1 (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
PE20180484A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
CO2019009815A2 (es) Combinaciones farmacéuticas
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX2025003354A (es) Anticuerpos que se unen a 5t4
CO2019005101A2 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
UY37914A (es) Anticuerpo monoclonal contr il-5r